melanoma is greater in whites compared with blacks. 5, 6 There has been no evidence for an increase in eye cancer incidence or mortality over the last 20 years in any part of the world, even in countries such as Australia which have seen a rapid increase in cutaneous melanoma cases.9,10 Furthermore, there is little variation in the incidence of uveal melanoma within or between countries.12 It is therefore probable that host factors play a greater role in the development of ocular melanoma than in cutaneous melanoma.
Epidemiological evidence for a genetic predisposition to uveal melanoma
Si1cock18 was the first to question whether there could be a hereditary basis for uveal melanoma when he reported a mother and daughter with the disease in 1892. Since A number of inherited susceptibility genes tend to cause cancer at several sites. Any excess of cancer in relatives at sites other than the eye may therefore reflect in part the pleiotropic effects of an inherited predisposition. There are a number of anecdotal reports of uveal melanoma in association with other cancers?S-30 One of the most spectacular of these is a family first reported by Silcock,18 which has been the subject of a recent follow-up study?8 Three of eight individuals who developed uveal melimoma also developed breast cancer (bilateral breast cancer in one case). Similarly striking is a case of bilateral uveal melanoma in association with primary bilateral ovarian carcinoma reported by Mullaney et az.29 A relationship between ocular melanoma and other cancers is supported by some,2°·32.34 but not all,31.33 systematic studies. In an analysis of 27 uveal melanoma families, Sing et aZ?O found the risk of a second primary was increased 4-fold. The most common malignancies observed in family members were breast, prostate and cutaneous melanoma. In a follow-up study of 32 251 women with ovarian cancer the risk of ocular melanoma was increased 4-fold?2 An increased risk of melanoma of the skin or eye has also been reported in a follow-up study of 18 010 breast cancer patients.34
Predisposition genes Approximately 10% of cutaneous melanomas arise in individuals with a family history of the disease. About 5% are truly hereditary;35.36 in these families predisposition to melanoma is transmitted as an autosomal dominant trait with variable penetrance?7 A number of these cases, linked to chromosome 9p13.22,38 are caused by mutations in the p16 gene (CDKN2A)?9,40 Individuals with multiple dysplastic naevi (dysplastic naevus syndrome, also known as atypical mole syndrome or AMS, are at increased risk of developing melanoma and are frequently observed in familial melanoma kindreds. 41, 42 In families where there is a family history of melanoma and dysplastic naevi, the risk of developing melanoma in susceptible individuals approaches 100%. Not all melanoma-prone families possess dysplastic naevi, so that the concordance of these two syndromes is not absolute.43,44 Given the common neural crest origin of uveal and skin melanocytes, any inherited syndrome associated with an increased uveal naevus count may be a precursor for some uveal melanomas. Uveal and conjunctival naevi all occur more commonly in patients with the dysplastic naevus syndrome. 45 Bataille et al. 46 examined the skin of 207 consecutive patients with ocular melanoma. Five patients had primary melanoma of the skin (relative risk of cutaneous melanoma 12.5). Furthermore, 3 of these 5 cases also had the AMS phenotype. Similarly in a systematic study of 109 uveal melanoma patients reported by van Hees et al. 47 2 patients had cutaneous melanomas and 4 had first-degree relatives affected with melanoma. The linking factor in three of the cases was AMS. The coexistence of ocular and cutaneous melanoma in both of these studies supports a predisposition to both types of melanomas in some family cancer syndromes, particularly AMS. Uveal melanoma risk is also related to the density of common naevi in a similar manner to cutaneous melanoma,4s and naevi are known to be strongly heritable. 49 Little is known about the molecular mechanisms involved in the development of uveal melanoma. In addition to the pOSSible involvement of the CDKN2A gene on chromosome 9, recent work strongly suggests that mutations in the breast cancer susceptibility locus, BRCA2 on chromosome 13, may also be involved.5o
Whilst the greatest cancer risks associated with BRCA2 mutations are breast and ovarian cancer, with lifetime risks of 84% and 27% respectively, 51 Mutations in genes such as BRCA2 are likely to confer a significant risk of uveal melanoma. In addition to this type of susceptibility gene, it is probable that there will be other predisposition genes for ocular melanoma that will confer more modest risks, but which will be more common. Candidates genes in this class are those that affect the host response to exogenous risk factors. Tissue response to ultraviolet irradiation is an important factor in determining melanoma risk and light skin and irides (blue, grey or green) are associated with an increased risk of uveal melanoma. Both of these traits are heritable.
The genetics of pigmentation are complex. It is known, however, that the relative proportions of phaemomelanin and eumelanin in tissues are regulated by melanocyte stimulating hormone (MSH), which acts via its receptor (MCIR) on melanocytes to increase the synthesis of eumelanin. In mice, mutations at the MC1R gene affect the pattern of melanogenesis, resulting in changes in coat colour. In man, MC1R sequence variants cause differences in the binding affinity of the MCIR for MSH56 and are found predominaIJ.tly in individuals with fair skin and blue eyes.57 Furthermore, MC1R variants have been shown to confer a 4-fold increase in risk of melanoma (95% CI, 1.48-10.35).58 It is conceivable that as well as being a risk factor for cutaneous melanoma, mutations in the MC1R gene could be a risk factor for ocular melanoma.
Conclusions
There is now considerable evidence that, like many cancers, a subset of uveal melanomas are caused by an inherited predisposition. Given that the prognosis associated with ocular melanoma is poor, an attractive proposition to reduce morbidity and mortality is to identify these susceptibility genes. This will allow those at risk to be identified and offered targeted surveillance or other measures. Furthermore, the identification of these genes should provide insights into the pathogenesis of uveal melanoma in general. At present the identification of a high-risk group is restricted to small numbers, comprising individuals from BRCA2 families and individuals with the AMS.
